⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL923419 | 0.95 | ALDH1A1 (0.41) | — | |
| SCHEMBL723777 | 0.70 | — | — | |
| SCHEMBL935229 | 0.70 | — | — | |
| SCHEMBL935566 | 0.70 | — | — | |
| SCHEMBL14859078 | 0.70 | — | — | |
| SCHEMBL28258686 | 0.70 | — | — | |
| SCHEMBL392829 | 0.70 | — | — | |
| SCHEMBL940899 | 0.70 | — | — | |
| SCHEMBL1850049 | 0.70 | KDM4E (0.43) | — | |
| SCHEMBL13698378 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115010826-A | Chitosan oligosaccharide-hydroxypyridone conjugate and preparation method and application thereof | 浙江工商大学 | 2022-09-06 | — | — | CN | disclosed |
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| WO-2018098204-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
| WO-2016079502-A1 | METAL CHELATING COMPOUNDS FOR USE IN TREATING DISEASES | UNIVERSITY OF NORTHUMBRIA (GB) | 2016-05-26 | — | — | WO | disclosed |
| US-9233937-B2 | Method of stimulating insulin secretion and/or modulating INS-1 kinase with substituted pyrazinones and/or substituted tetrahydroquinoxalinones | MERCK PATENT GMBH (FR) | 2016-01-12 | — | — | US | disclosed |
| US-9102632-B2 | Pyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2015-08-11 | — | — | US | disclosed |
| EP-2250156-B1 | PYRAZINONE DERIVATIVES AS INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-20140329837-A1 | ARYLPYRAZINONES SUCH AS BUT NOT LIMITED TO 3-(4-CHLOROPHENYL-1-ETHYLPYRAZIN-2-(1H0)-ONE | MERCK PATENT GMBH (FR) | 2014-11-06 | — | — | US | disclosed |
| US-8815859-B2 | Substituted pyrazin-2-ones and substituted 5,6,7,8-tetrahydroquinoxalin-2-ones and methods of use thereof | MERCK PATENT GMBH (DE) | 2014-08-26 | — | — | US | disclosed |
| EP-1189899-A1 | PYRAZINONE THROMBIN INHIBITORS | Merck & Co., Inc. (US) | 2002-03-27 | — | — | EP | disclosed |
| US-20020035115-A1 | Thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2002-03-21 | — | — | US | disclosed |
| WO-2002009711-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2002006248-A2 | CYCLIC OXYGUANIDINE PYRAZINONES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
| US-20020006923-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-01-17 | — | — | US | disclosed |
| US-20020004507-A1 | Pyrazinone thrombin inhibitors | MERCK SHARP & DOHME CORP. | 2002-01-10 | — | — | US | disclosed |
| WO-2001092234-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001070229-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| WO-2001038323-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| WO-2000075134-A1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2000-12-14 | — | — | WO | disclosed |